Ari Grinspan is a Gastroenterology physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 111 publications with 2,829 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
17 E 102nd St
New York, NY 100295204
Telephone
212-241-8100Registry record last updated 22 Feb 2019.
Clinical trials
- MTC Versus FMT in for RCDI
Sponsor: Icahn School of Medicine at Mount Sinai
- Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)
Sponsor: Ari M Grinspan
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20259 payments
- ABBVIE INC.Program year202511 payments
- Ferring Pharmaceuticals Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
90.6%Proton pump inhibitor55.7%Omeprazole58%Pantoprazole Sodium35%Esomeprazole Magnesium8%Part D<11 patientsH2 blocker9.6%Famotidine100%Part D≥12 patients+ 6 more classes in this area
Nervous system
9.4%Tricyclic Antidepressant9.4%Amitriptyline Hcl61%Nortriptyline Hcl40%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2024 per NIH RePORTER. The latest:
- Comparison of defined live biotherapeutic product and fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection
Icahn School of Medicine at Mount Sinai
FY2024$324,480R01DK130337 - Comparison of defined live biotherapeutic product and fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection
Icahn School of Medicine at Mount Sinai
FY2023$338,000R01DK130337 - Comparison of defined live biotherapeutic product and fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection
Icahn School of Medicine at Mount Sinai
FY2022$338,000R01DK130337
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Credible inferences in microbiome research: ensuring rigour, reproducibility and relevance in the era of AI
Nature Reviews Gastroenterology & Hepatology
2025 - Microbiota therapeutics for inflammatory bowel disease: the way forward
The Lancet. Gastroenterology & hepatology
2024 - Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection
The American Journal of Gastroenterology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”